Search

Your search keyword '"Newsom-Davis, Thomas"' showing total 171 results

Search Constraints

Start Over You searched for: Author "Newsom-Davis, Thomas" Remove constraint Author: "Newsom-Davis, Thomas"
171 results on '"Newsom-Davis, Thomas"'

Search Results

1. Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

2. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

3. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

4. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

6. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

8. Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot

9. Fas Ligand and Tumour Immunology

11. Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

12. Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

13. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

18. 512 Time-of-day of pembrolizumab infusion and clinical outcomes of patients with NSCLC: too soon to promote morning infusions

19. Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer

21. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

22. Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry

23. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

24. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.

25. Persistence of long-term COVID-19 sequelae in patients with cancer:An analysis from the OnCovid registry

27. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

28. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

29. Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study

30. Abstract 701: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

31. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study

32. sj-docx-1-tam-10.1177_17588359211053416 ��� Supplemental material for COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

34. CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.

35. COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry.

36. Abstract S01-03: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

37. Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe

38. Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective

39. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

41. List of Contributors

43. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

44. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe

45. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

47. Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the TAIL study.

49. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

Catalog

Books, media, physical & digital resources